The reason for exploring KRAS mutation status as a prognostic biomarker rather than any other potentially useful biomarkers, such as Ki67, is that these patients were being screened for potential inclusion in a clinical study of EGFR inhibition in KRAS wild-type pancreatic cancer [22]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.